medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Group A streptococcal meningitis with the $M1_{UK}$ variant in the Netherlands

Boas C.L. van der Putten[1], PhD, Bart J.M. Vlaminckx[2], MD, PhD, Brechje de Gier[1,3], PhD, Wieke Freudenburg-de Graaf[3,4], MD, PhD, Nina M. van Sorge[3,4], PhD

[1]National Institute for Public Health and the Environment, Bilthoven, Netherlands; [2]Department of Medical Microbiology and Immunology, St Antonius Hospital, Nieuwegein, Netherlands; [3]Department of Medical Microbiology and Infection Prevention, [4]Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam UMCs, Amsterdam, Netherlands.

Corresponding author: Prof. dr. N.M. van Sorge, Department of Medical Microbiology and Infection Prevention, Netherlands Reference Laboratory for Bacterial Meningitis, Amsterdam UMCs location University of Amsterdam, Meibergdreef 9, IWO building IA3.159, 1105 AZ Amsterdam, the Netherlands; email address: n.m.vansorge@amsterdamumc.nl; phone number +31-205664862

Date of revision: 17 March 2023

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

We analyzed over 40 years of bacteriological surveillance data to reveal a 4-fold increase in Group A streptococcal (GAS) meningitis in 2022 compared to the annual average of 1982-2021 (n=5/year). Already 10 GAS meningitis cases occurred in 2023 (until March 13th). Molecular typing revealed that 25 out-of-29 (86%) isolates received in 2022 and 2023 were *emm*1.0 (Figure 1). WGS analysis of 19 *emm*1.0 isolates (2019 until 20th December 2022) demonstrated that 15 out-of-19 (79%) isolates belonged to the toxicogenic $M1_{UK}$ lineage. Based on these observations, we urge clinicians to be vigilant regarding clinical sign of meningitis with invasive GAS infections, since this disease manifestation appears to have a higher than expected occurrence due to clonal replacement by the recently-emerged $M1_{UK}$ variant.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Streptococcus pyogenes can cause a wide range of invasive infections, collectively referred to as invasive group A streptococcal (iGAS) infections. A rare but severe disease manifestation of iGAS is meningitis, which has an estimated incidence in adults of 0.2 per 1,000,000 persons per year [1,2]. Several European countries as well as the United States have observed an increase of iGAS infections in the past months, with shifts in affected age groups and clinical presentations relative to historic observations [3,4]. Here we performed an epidemiological assessment of *S. pyogenes* meningitis cases, defined by culture-positive cerebrospinal fluid (CSF), using over 40 years of national bacteriological surveillance data.

Methods

Active microbiological surveillance and molecular epidemiology of all-cause bacterial meningitis, including *S. pyogenes*, is performed by the Netherlands Reference Laboratory for Bacterial Meningitis (NRLBM). We analyzed *S. pyogenes* isolates cultured from CSF between 1982-2023 (until March 13th). Typing of *S. pyogenes* has been based on sequence variation in 180 bp of the *emm* gene and is routinely performed since 2013 according to the Centers of Disease Control and Prevention protocol (https://www.cdc.gov/streplab/groupa-strep/resources.html). To distinguish between the recently-identified toxicogenic $M1_{UK}$ variant and the $M1_{global}$ strains [5], *emm*1.0 isolates received between 2019 and 20th Dec 2022 were analyzed by whole-genome sequencing (WGS; Illumina HiSeq). In accordance with Dutch law, approval by a medical ethics committee was not deemed necessary since cases were not subject to any actions or rules of conduct. No informed consent was requested and only pseudonymized data were used for the study.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Results

Between 1982 and 2021, the NRLBM received 216 *S. pyogenes* CSF isolates, with an annual mean of five isolates (range 1-15). In contrast, 19 *S. pyogenes* CSF isolates were received in 2022, and 10 isolates were received between January 1 and March 13, 2023.

Among the 48 CSF isolates from 2013-2021, 19 different *emm* (sub)types were distinguished, with *emm*1.0 being the dominant *emm*-type at 35% (n=17; Figure 1),[6]. However, from the 29 *S. pyogenes* CSF isolates that have been received between 2022 and 13th March 2023, 25 out-of-29 (86%) isolates were *emm*1.0 (Figure 1). Using WGS analysis for a smaller selection of *emm*1.0 isolates (2019 until 20th December 2022), 15 out-of-19 (79%) isolates belonged to the toxicogenic $M1_{UK}$ lineage[5], with all *emm*1.0 isolates received from May 2022 onwards representing the $M1_{UK}$ variant. The 15 $M1_{UK}$ isolates originated from different municipalities, spread across the Netherlands. The age distribution of meningitis patients caused by *emm*1.0 strains was similar in 2022-2023 compared to 2013-2021 (Figure 2).

Discussion

Since 2022, an increase in *S. pyogenes* meningitis, with strong overrepresentation of the *emm*1.0 type and $M1_{UK}$ variant, has been observed in the Netherlands. This study considered meningitis patients based on *S. pyogenes* cultured from CSF to provide a consistent comparison over time. Study limitations include the exclusion of meningitis patients with only a positive *S. pyogenes* blood culture, resulting in an underestimation of the overall national occurrence of *S. pyogenes* meningitis, and the small number of CSF isolates with limited patient information, which precluded more in-depth statistical and clinical evaluation. Furthermore, submission bias to the NRLBM may play a role, given the increased general

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

submission of *S. pyogenes* isolates throughout 2022. Data from other countries are needed to assess whether the here observed increase in *S. pyogenes* meningitis is more widespread. The strong overrepresentation of *emm*1.0 among the received CSF isolates underlines the invasiveness of this *emm* type [5]. Moreover, the dominance of the toxicogenic $M1_{UK}$ variant among *emm*1.0 CSF isolates suggests an extensive replacement of circulating *S. pyogenes* *emm*1.0 strains. Detailed clinical studies are required to assess whether iGAS infections caused by the $M1_{UK}$ variant are generally more severe. Clinicians are urged to be vigilant regarding the occurrence of meningitis with *S. pyogenes*, as this disease manifestation appears to have a higher than expected incidence with the recently emerged $M1_{UK}$ variant.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .



Figure 1. Number of received *S. pyogenes* CSF isolates with proportion of *emm*1.0, 2013-2023 (until March 13th).



Figure 2. Age distribution of *S. pyogenes* meningitis patients infected with *emm*1.0 or other *emm* types in 2013-2021 versus 2022-2023. * Until March 13th 2023.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

Acknowledgements

The authors would like to thank Agaath Arends-van 't Klooster, Wendy Bril-Keijzers, Ilse de Beer-Schuurman, Jolein Pleijster, and Claudia Burger for their continued contributions as research technicians of the NRLBM (Amsterdam UMCs, Department of Medical Microbiology and Infection Prevention, Amsterdam, The Netherlands). Data are available upon request to the corresponding author with exception of specific patient information which will only be provided in aggregated form. NMvS declares fee for service and consultancy fees directly paid to the institution from MSD and GSK outside the submitted work. NMvS declared royalties related to a patent (WO 2013/020090 A3) on vaccine development against *Streptococcus pyogenes* (Vaxcyte; Licensee: University of California San Diego with NMvS as co-inventor). NMvS is a member of the Science advisory Board for the ItsME foundation (unpaid) and Rapua te me ngaro ka tau project (paid to institution; Project facilitating Strep A vaccine development for Aotearoa New Zealand). Other authors declare no conflict of interest.

References

1. Lucas MJ, Brouwer MC, Bovenkerk S, Man WK, van der Ende A, van de Beek D. Group A Streptococcal meningitis in adults. *J Infect.* 2015;71(1):37-42.
2. Kjaergaard N, Bodilsen J, Justesen US, et al. Community-acquired meningitis caused by beta-haemolytic streptococci in adults: a nationwide population-based cohort study. *European journal of clinical microbiology & infectious diseases.* 2019;38(12):2305-2310.
3. Holdstock V, Twynam-Perkins J, Bradnock T, et al. National case series of group A streptococcus pleural empyema in children: clinical and microbiological features. *Lancet Infect Dis.* 2023;23(2):154-156.

medRxiv preprint doi: https://doi.org/10.1101/2023.02.27.23286423; this version posted March 20, 2023. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .

4. van Kempen EB, Bruijning-Verhagen PCJ, Borensztajn D, et al. Increase in Invasive Group a Streptococcal Infections in Children in the Netherlands, A Survey Among 7 Hospitals in 2022. *Pediatr Infect Dis J.* 2023;42(4):e122-e124.

5. Lynskey NN, Jauneikaite E, Li HK, et al. Emergence of dominant toxigenic M1T1 *Streptococcus pyogenes* clone during increased scarlet fever activity in England: a population-based molecular epidemiological study. *Lancet Infect Dis.* 2019;19(11):1209-1218.

6. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global emm type distribution of group A streptococci: systematic review and implications for vaccine development. *Lancet Infect Dis.* 2009;9(10):611-616.